From article: "Federal regulators are scheduled to approve or reject Alnylam's rare disease drug, patisiran, by Aug. 11. If approved, patisiran would be the 16-year-old company's first product to market and is projected to bring in $1 billion annually by 2023."
"Alnylam is preparing for a positive FDA outcome: It has added two more office spaces in the highly sought after Kendall Square area, including a Main Street site that the company originally had intended to rent during construction."
This looks like a good time to buy in for a good long play.
Submitted August 07, 2018 at 01:20PM by TheBigMac17 https://ift.tt/2AReCh0
No comments:
Post a Comment